18F-fluoride PET: Changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)

EJNMMI Research

Volumn 1, Issue 1, 2011, Pages 1-6

  Cook, Gary J R ^a   Parker, Chris ^a   Chua, Sue ^a   Johnson, Bernadette ^a   Aksnes, Anne Kirsti ^b   Lewington, Val J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Algeta AS   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223;

ADULT; AGED; ARTICLE; BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG UPTAKE; HUMAN; INTERMETHOD COMPARISON; MALE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME;

EID: 84875912339     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-1-4     Document Type: Article

References (22)

1. Prostate cancer-UK incidence statistics. [http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/#geog].
2. Rubens RD: Bone metastases-incidence and complications. In Cancer and the skeleton. Edited by: Rubens RD, Mundy GR. London: Martin Dunitz; 2000:33-42.
3. Clamp A, Danson S, Nguyen H, Cole D, Clemons M: Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 2004, 5:607-616.
4. Therasse P, Arbuck E, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000, 92:205-216.
5. Haywood JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977, 13:89-94.
6. Coombes RC, Dady P, Parsons C, McCready VR, Ford HT, Gazet JC, Powles TJ: Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer 1983, 52:610-614.
7. Sundkvist GM, Ahlgren L, Lilja B, Mattsson S, Abrahamsson PA, Wadström LB: Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchidectomy. Eur J Nucl Med 1988, 14:203-206.
8. Sundkvist GM, Björk T, Kjellström H, Lilja B: Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues. Scand J Urol Nephrol 1996, 30:29-32.
9. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI: A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res 1998, 4:1765-1772.
10. Rydh A, Ahlström KR, Larsson A, Johansson L, Damber JE, Tomiç R, Hietala SO: Quantitative bone scintigraphy. A methodological evaluation in prostate cancer. Acta Radiol 2000, 41:183-188.
11. Condon BR, Buchanan R, Garvie NW, Ackery DM, Fleming J, Taylor D, Hawkes D, Goddard BA: Assessment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imaging. Br J Radiol 1981, 54:18-23.
12. Blau M, Nagler W, Bender MA: Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962, 3:332-334.
13. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Träger H, Nüssle K, Reske SN: Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999, 40:1623-1629.
14. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, Messer P, Nüssle K, Elsner K, Glatting G, Träger H, Neumaier B, Diederichs C, Reske SN: Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and PET. J Clin Oncol 1999, 17:2381-2389.
15. Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, Dziuk K, Gabelmann A, Reske SN, Hetzel M: Evaluation of the clinical value of planar bone scans, SPECT and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001, 42:1800-1804.
16. Kruger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, Wibmer T, Merk T, Hombach V, Reske SN: Detection of bone metastases in patients with lung cancer: 99mTc MDP planar bone scintigraphy, 18Ffluoride PET or 18F-FDG PET-CT. Eur J Nucl Med Mol Imaging 2009, 36:1807-1812.
17. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I: The detection of bone metastases in patients with high risk prostate cancer: 99mTc MDP planar bone scintigraphy, single and multi field of view SPECT, 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2006, 47:287-297.
18. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E: Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004, 45:272-278.
19. Uchida K, Nakajima H, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, Tsuchida T, Okazawa H, Fujibayashi Y, Baba H: Effects of Alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. J Nucl Med 2009, 50:1808-1814.
20. Blake GM, Park-Holohan SJ, Cook GJR, Fogelman I: Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med 2001, 31:28-49.
21. Wade AA, Scott JA, Kuter I, Fischman AJ: Flare response in 18F-fluoride ion PET bone scanning. AJR 2006, 186:1783-1786.
22. Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I: Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 1988, 29:1354-1359.